Secondary objectives included assessing the combined utility of CD133 expression in CTCs and CEA levels for prognostic evaluation and exploring the associations between CD133-positive CTCs and clinicopathological factors, such as tumor stage, grade, and metastatic potential. Here, CEACAM5 is linked to neoplasm.